Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting
Doxorubicin (DOX), a widely used drug in cancer chemotherapy, induces cell death via multiple intracellular interactions, generating reactive oxygen species and DNA-adducted configurations that induce apoptosis, topoisomerase II inhibition, and histone eviction. Despite its wide therapeutic efficacy...
Huvudupphovsmän: | Jihoon Lee, Min-Koo Choi, Im-Sook Song |
---|---|
Materialtyp: | Artikel |
Språk: | English |
Publicerad: |
MDPI AG
2023-05-01
|
Serie: | Pharmaceuticals |
Ämnen: | |
Länkar: | https://www.mdpi.com/1424-8247/16/6/802 |
Liknande verk
Liknande verk
-
Molecular mechanisms associated with the chemoprotective role of protocatechuic acid and its potential benefits in the amelioration of doxorubicin-induced cardiotoxicity: A review
av: Edozie S. Okpara, et al.
Publicerad: (2022-01-01) -
UHPLC-MS/MS Assay for Quantification of Legubicin, a Novel Doxorubicin-Based Legumain-Activated Prodrug, and Its Application to Pharmacokinetic and Tissue Distribution Studies
av: Liyuan Ma, et al.
Publicerad: (2024-02-01) -
Salvage Chemotherapy in Recurrent Cervical Cancer With Biweekly Pegylated Liposomal Doxorubicin (Lipo-Dox)
av: Jen-Ruei Chen, et al.
Publicerad: (2008-09-01) -
Targeting mitochondrial dynamics proteins for the treatment of doxorubicin-induced cardiotoxicity
av: Rui Chen, et al.
Publicerad: (2023-08-01) -
Quantitative analysis of doxorubicin hydrochloride and arterolane maleate by mid IR spectroscopy using transmission and reflectance modes
av: Ranju Bansal, et al.
Publicerad: (2021-04-01)